A cell-permeable peptide that binds to Bcl-2 with high affinity (IC50 = 130 nM in a competition binding study) and induces apoptosis. Displays antitumor activity in cells overexpressing Bcl-2 with no apparent effect on normal peripheral lymphocytes. The peptide is derived from the BH3 domain (residues 140 - 165, a “death domain”) of Bad and is modified to be cell permeant by attaching a decanoyl moiety at the N-terminus.
A cell-permeable Bcl-2 binding peptide that induces apoptosis in Bcl-2 expressing cells with no apparent effect on normal peripheral lymphocytes. Also reported to diminish the growth of human myeloid leukemia in severe combined immunodeficient mice. The peptide is derived from the BH3 domain (residues 140-165, a death domain) of Bad and is modified to be cell-permeable by attaching a decanoyl moiety at the N-terminus.
1 mg in Plastic ampoule
Packaged under inert gas
Acciones bioquímicas o fisiológicas
Product does not compete with ATP.
Target IC50: 130 nM against Bcl-2
Cell permeable: yes
Toxicity: Standard Handling (A)
Supplied as a trifluoroacetate salt.
Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 2 weeks at -20°C.
Wang, J-L., et al. 2000. Cancer Res.60, 1498.
Kelekar, A., et al. 1997. Mol. Cell. Biol.17, 7040.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany